Apogee Q3 2024 Earnings Report

Reported pipeline progress and third quarter financial results.

Key Takeaways

Apogee Therapeutics reported its Q3 2024 financial results, highlighting continued execution across all programs, including positive results from the APG777 Phase 1 trial. The company is on track to report Phase 2 Part A data for APG777 in 2H 2025, interim Phase 1 data for APG808 in 4Q 2024, and interim Phase 1 data for APG990 in 1H 2025. Apogee had $753.8 million in cash, cash equivalents, and marketable securities, providing runway into 2028.

Reported positive results up to nine months from APG777 Phase 1 trial.

On track to report Phase 2 Part A data for APG777 in 2H 2025, interim Phase 1 data for APG808 in 4Q 2024 and interim Phase 1 data for APG990 in 1H 2025.

APG333 development candidate selected and accelerating initiation of Phase 1 in late 2024 or early 2025.

Cash, cash equivalents and marketable securities of $753.8 million with runway into 2028.

Previous year: -$0.51